When combined with nivolumab, RP1 induced systemic responses in patients with advanced melanoma who have failed to respond to prior anti–PD-1 therapy, according to findings from the phase I/II IGNYTE ...
Adding a third immune-targeting drug to existing therapies may help to shrink tumors in laboratory models of treatment-resistant melanoma, according to new research.
Scleral lenses present an innovative solution for drug delivery in ocular therapy, enhancing treatment outcomes and patient comfort. — Michelle K. Man.
Contact Lens Spectrum
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Emails and interviews show CDC scientists were sidelined during the West Texas surge, leaving local officials without guidance as cases spread across the US and into Mexico.